• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by IDEXX Laboratories Inc. (Amendment)

    2/9/23 11:22:21 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $IDXX alert in real time by email
    SC 13G/A 1 tv01128-idexxlaboratoriesinc.htm SCHEDULE 13G/A idexxlaboratoriesinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 10)*

    Name of issuer:  IDEXX Laboratories Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  45168D104

    Date of Event Which Requires Filing of this Statement: December 30, 2022

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  45168D104

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    123,543

    7.  SOLE DISPOSITIVE POWER

    7,784,587

    8.  SHARED DISPOSITIVE POWER

    347,892

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    8,132,479

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    9.82%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    IDEXX Laboratories Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    One IDEXX Drive
    Westbrook, ME 04092-2040

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    45168D104

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2023

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $IDXX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IDXX

    DatePrice TargetRatingAnalyst
    12/2/2024$500.00Outperform
    Leerink Partners
    7/25/2024$580.00Buy
    BTIG Research
    1/30/2024$525.00Overweight → Neutral
    Piper Sandler
    12/7/2023$602.00Outperform
    Exane BNP Paribas
    12/4/2023Neutral → Buy
    Cleveland Research
    8/2/2023$610.00Overweight → Neutral
    Atlantic Equities
    7/25/2022$415.00Buy → Hold
    Stifel
    7/21/2022$530.00 → $435.00Neutral → Buy
    Goldman
    More analyst ratings

    $IDXX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • IDEXX Laboratories Announces First Quarter Results

      Achieves first quarter revenue growth of 4% as reported and 5% organic, supported by CAG Diagnostics recurring revenue growth of 3% as reported and 4.5% organic. Organic revenue growth supported by benefits from IDEXX execution drivers, including continued solid new business gains and strong year-over-year global premium instrument installed base growth, including over 300 IDEXX inVue Dx™ placements. Delivers EPS of $2.96, an increase of 5% as reported and 7% on a comparable basis, supported by gross margin expansion of 90 basis points as reported and 80 basis points on a comparable basis. Adjusts 2025 revenue guidance to $4,095 million - $4,210 million, an increase of $40 million

      5/1/25 6:30:00 AM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • IDEXX Laboratories to Release 2025 First Quarter Financial Results

      IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 first quarter financial results for Thursday, May 1, 2025, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q1 2025 Earnings Snapshot through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. ET on that day via the same link and will remain available for one year. The live call also will be accessible by telephone. To listen to t

      4/3/25 1:30:00 PM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • IDEXX Laboratories to Present at Two Upcoming Institutional Investor Conferences

      IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, will participate in two upcoming conferences: Thursday, February 27, 9:05 am – 9:45 am EST – Mike Erickson, PhD, Executive Vice President, and General Manager, Point of Care Diagnostics and Telemedicine, and Andrew Emerson, Senior Vice President, Corporate and CAG Finance, will participate in a fireside chat at the virtual BofA Securities Animal Health Summit. Monday, March 3, 11:35 am – 12:05 pm EST – Jay Mazelsky, President and Chief Executive Officer, will present at the 46th Annual Raymond James Institutional Investors Conference. Live webcasts of the presentations will be available through li

      2/13/25 2:00:00 PM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $IDXX
    Leadership Updates

    Live Leadership Updates

    See more
    • First Watch Announces Appointment of Irene Chang Britt to Board of Directors

      BRADENTON, Fla., July 19, 2023 (GLOBE NEWSWIRE) -- First Watch Restaurant Group, Inc. (NASDAQ:FWRG) ("First Watch" or the "Company"), the leading Daytime Dining concept serving breakfast, brunch and lunch, today announced the appointment of Irene Chang Britt to its Board of Directors, effective immediately. Ms. Chang Britt is an experienced independent board director and former Fortune 500 C-suite executive, who currently serves on the boards of established businesses and start-up companies representing a variety of industries, including retail, CPG, e-commerce and lifestyle. "We are thrilled to welcome Irene to the Board of Directors of First Watch, and I'm confident that our company wil

      7/19/23 4:15:00 PM ET
      $BHF
      $FWRG
      $IDXX
      $VSCO
      Life Insurance
      Finance
      Restaurants
      Consumer Discretionary
    • Ocular Therapeutix™ Appoints Merilee Raines to Its Board of Directors

      Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Merilee Raines to the Company's Board of Directors effective September 20, 2021. "We are excited to welcome Merilee to our Board of Directors," said Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix. "Merilee brings a wealth of operational, financial, and business experience to our team. Having started as employee #11 at IDEXX, she helped to drive a multitude of innovative growth strategies and successfully scaled the business from sta

      9/22/21 8:00:00 AM ET
      $IDXX
      $OCUL
      $TMDX
      $WTS
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Electromedical & Electrotherapeutic Apparatus

    $IDXX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by IDEXX Laboratories Inc.

      SC 13G/A - IDEXX LABORATORIES INC /DE (0000874716) (Subject)

      11/12/24 3:48:28 PM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SC 13G/A filed by IDEXX Laboratories Inc.

      SC 13G/A - IDEXX LABORATORIES INC /DE (0000874716) (Subject)

      11/4/24 11:47:05 AM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by IDEXX Laboratories Inc. (Amendment)

      SC 13G/A - IDEXX LABORATORIES INC /DE (0000874716) (Subject)

      2/13/24 5:06:19 PM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $IDXX
    SEC Filings

    See more
    • SEC Form 10-Q filed by IDEXX Laboratories Inc.

      10-Q - IDEXX LABORATORIES INC /DE (0000874716) (Filer)

      5/1/25 4:11:17 PM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • IDEXX Laboratories Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - IDEXX LABORATORIES INC /DE (0000874716) (Filer)

      5/1/25 6:30:23 AM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form DEF 14A filed by IDEXX Laboratories Inc.

      DEF 14A - IDEXX LABORATORIES INC /DE (0000874716) (Filer)

      3/28/25 4:00:25 PM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $IDXX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Emerson Andrew claimed ownership of 2,396 shares (SEC Form 3)

      3 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)

      3/10/25 7:12:33 PM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • EVP, CFO and Treasurer Mckeon Brian P converted options into 1,162 shares and covered exercise/tax liability with 569 shares, increasing direct ownership by 2% to 31,550 units (SEC Form 4)

      4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)

      2/18/25 9:44:17 PM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • EVP, GC & Corporate Secretary Underberg Sharon E. was granted 704 shares and covered exercise/tax liability with 219 shares, increasing direct ownership by 9% to 6,127 units (SEC Form 4)

      4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)

      2/18/25 9:44:07 PM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $IDXX
    Financials

    Live finance-specific insights

    See more
    • IDEXX Laboratories Announces First Quarter Results

      Achieves first quarter revenue growth of 4% as reported and 5% organic, supported by CAG Diagnostics recurring revenue growth of 3% as reported and 4.5% organic. Organic revenue growth supported by benefits from IDEXX execution drivers, including continued solid new business gains and strong year-over-year global premium instrument installed base growth, including over 300 IDEXX inVue Dx™ placements. Delivers EPS of $2.96, an increase of 5% as reported and 7% on a comparable basis, supported by gross margin expansion of 90 basis points as reported and 80 basis points on a comparable basis. Adjusts 2025 revenue guidance to $4,095 million - $4,210 million, an increase of $40 million

      5/1/25 6:30:00 AM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • IDEXX Laboratories to Release 2025 First Quarter Financial Results

      IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 first quarter financial results for Thursday, May 1, 2025, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q1 2025 Earnings Snapshot through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. ET on that day via the same link and will remain available for one year. The live call also will be accessible by telephone. To listen to t

      4/3/25 1:30:00 PM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • IDEXX Laboratories Announces Fourth Quarter and Full Year 2024 Results

      Achieves fourth quarter revenue growth of 6% as reported and on an organic basis, driven by CAG Diagnostics recurring revenue growth of 6% reported and 7% organic Solid growth supported by continued benefits from IDEXX execution drivers, including 9% year-over-year expansion of IDEXX's global premium instrument installed base and net customer gains across testing modalities Delivers fourth quarter EPS of $2.62, an increase of 13% as reported and 10% on a comparable basis driven by strong operating results Provides initial outlook for 2025 revenue of $4,055 million - $4,170 million, reflecting growth of 4% - 7% reported and 6% - 9% organic, supported by CAG Diagnostics recurring

      2/3/25 6:30:00 AM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $IDXX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Leerink Partners initiated coverage on IDEXX Labs with a new price target

      Leerink Partners initiated coverage of IDEXX Labs with a rating of Outperform and set a new price target of $500.00

      12/2/24 6:57:33 AM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • BTIG Research initiated coverage on IDEXX Labs with a new price target

      BTIG Research initiated coverage of IDEXX Labs with a rating of Buy and set a new price target of $580.00

      7/25/24 6:47:32 AM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • IDEXX Labs downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded IDEXX Labs from Overweight to Neutral and set a new price target of $525.00

      1/30/24 6:59:50 AM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care